Novel isoelectric target depletion (ITaD) protocol reduces the need for specific reagents for immunogenicity testing

Gregor Jordan1, Miriam Moheysen-Zadeh1, Uwe Dahl1

  • 1Roche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Bioanalytics & Biomarker, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, 82377, Germany.

Bioanalysis
|June 1, 2022
PubMed

Related Concept Videos